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. S. aureus is the causative agent of a series of diseases ranging from moderately severe skin infections to fatal necrotizing pneumonia and is one of the most frequent causes of morbidity and mortality throughout the world 2 . It has been estimated that in the United States, S. aureus infections cost more lives than HIV/AIDS 3 . Other species in the genus, such as S. epidermidis, are commonly opportunistic and cause chronic disease 4 , which often proceeds with the involvement of biofilms -sticky, cellular agglomerations that protect the constituent bacteria from antibiotics and host defences 5 .
The frequent occurrence of antibioticresistant strains and the lack of an FDAapproved vaccine strategy severely complicate treatment of staphylococcal infections.
The virulence potential of S. aureus is defined to a large extent by its capacity to produce a plethora of different toxins, many of which target mechanisms of host defence 6 . Some S. aureus toxins are encoded in mobile genetic elements (MGEs) and are thus limited to a subset of S. aureus isolates, whereas others are encoded in the S. aureus core genome or in highly conserved genomic islands and so are produced by virtually all strains. Among the latter toxins, phenol-soluble modulins (PSMs) have recently attracted much attention because they have been found to have a key impact on the pathogenesis of S. aureus infections 7, 8 . PSMs were first identified in 1999 with the description of a "pro-inflammatory complex" isolated by hot phenol extraction from S. epidermidis culture filtrate, in which three peptides termed PSMα, PSMβ and PSMγ were identified 9 ; PSMγ is identical to the previously described S. epidermidis δ-toxin 10 , which is the preferred term for this molecule. Although more recent analysis of PSM-receptor interactions 11 suggests that the Toll-like receptor 2 (TLR2)-stimulating capacities attributed to PSMs in the initial studies 9, [12] [13] [14] were probably caused at least in part by impurities, the apparent immunestimulatory function paved the way for further investigation.
Subsequent experiments led to the identification of S. aureus PSMs that kill human neutrophils and have a major impact on the ability of the recently emerged communityassociated methicillin-resistant S. aureus (CA-MRSA) strains to cause disease 7 . Since then, many reports have been published delineating the roles of PSMs in the pathogenesis and physiology of S. aureus. PSMs have also been recognized to contribute to phenotypes not associated with infection, potentially representing the 'original' role of PSMs, from which other roles as virulence factors evolved 15 . Here, we focus on the roles of PSMs in staphylococcal infection and discuss the mechanisms underlying their contribution to pathogenesis. We also discuss how PSMs could be targeted for the development of anti-staphylococcal drugs.
PSMs: genetic and biochemical properties
The complement of PSMs in staphylococci varies such that the range of molecules is specific for a given species 7, 16, 17 . PSM nomenclature is not consistent. In S. epidermidis, they were given consecutive Greek letters on discovery, whereas in S. aureus they were named with Greek letters according to the grouping of PSMs into the smaller α-type and the larger β-type group (see below); in our opinion, the latter nomenclature should be kept to designate PSMs discovered in the future. PSM peptides in different species can have the same name but different amino acid sequences, and it is therefore best to always refer to a PSM peptide with its name and producing species together.
In S. aureus, PSMs are encoded at three different locations in the genome 7 . Four PSMα peptides, PSMα1-PSMα4, are encoded in the psmα operon; PSMβ1 and PSMβ2 are encoded in the psmβ operon; and δ-toxin is encoded within the coding sequence for RNAIII, the RNA effector molecule of the accessory gene regulator (Agr) quorum-sensing system 18 . Other than for S. aureus, the only other staphylococcal species for which there is complete information about the encoded PSM peptides is S. epidermidis, which produces PSMα, PSMβ1, PSMβ2, PSMδ, PSMε and δ-toxin (see FIG. 1 
PSM peptides are grouped according to their length: the α-type peptides (S. aureus PSMα1-PSMα4 and δ-toxin, and S. epidermidis PSMα, PSMδ, PSMε and δ-toxin) are ~20-25 amino acids long, whereas the β-type peptides (S. aureus and S. epidermidis PSMβ1 and PSMβ2) are ~44 amino acids in length.
Other than for those PSM peptides that are encoded together in one operon, and which apparently arose from gene duplication events, the amino acid sequence . Several α-type psm genes are not annotated in staphylo coccal genomes owing to their short length. Note that the psmα and psmδ genes of S. epidermidis are located at a position in the genome corresponding to that of the S. aureus psmα operon, suggesting these genes have a common ancestor. The S. epidermidis psmβ operon contains a gene, psmβ3, the product of which cannot be detected in culture filtrates of S. epidermidis strains. Some S. epidermidis strains, such as strain RP62A, contain two identical copies of psmβ1, resulting in higher PSMβ1 production than in strains that contain only one copy. The δ-toxin (sometimes called PSMγ), which is highly similar between S. epidermidis and S. aureus, is encoded by the gene hld (haemo lysin delta), which is located within rNAIII in the accessory gene regulator (Agr) system. Numbers following the amino acid sequences show the peptide length, and charge in parentheses. Yellow boxes indicate the amphipathic α-helix. c | Location of the psm-mec gene in staphylococcal cassette chromosome mec (SCCmec) elements. The psm-mec gene is found in SCCmec elements of types II, III and VIII, in the J2 region next to the class A mec gene complex (with the core genes of the SCCmec element in the order IS431-mecA-mecR-mecI), which is characteristic of these SCCmec types. The SCCmec type III element is shown here as an example. d | α-helical wheel presentation of PSMα3, showing the extreme amphipathy that is characteristic of PSMs, with hydrophobic and hydrophilic amino acids found on opposite sides of the α-helix. The characteristic surfactant-like properties that are caused by the pronounced amphipathy of PSMs are reflected by, for example, the tendency of PSMs to aggregate in oligomers, and their capacity to facilitate spreading on surfaces 21 or to structure biofilms 22, 23 . These features probably have a role in promoting colonization of the skin and emulsifying nutrients in that environment, and might constitute the 'original' purpose of PSMs before some evolved to fulfil roles in pathogenesis (for example, by disrupting primitive phagocytes) 15 . Some PSM-like peptides had been previously reported in other staphylococcal species. For example, the slush peptides of Staphylococcus lugdunensis 24 and the gonococcal growth inhibitor peptides from Staphylococcus haemolyticus 25 are now known to belong to the PSMβ family. Several other PSM peptides in staphylococcal species other than S. aureus and S. epidermidis were found by liquid chromatography-mass spectrometry, but their amino acid sequences and encoding genes have not yet been identified 17 . Notably, for many of the biological functions of PSMs described below, it is important that they are under exceptionally strict and direct regulation by the Agr quorum-sensing system, which promotes strong enhancement of PSM production at high cell density 26, 27 (FIG. 2) . In contrast to most other genes in the Agr regulon, which are regulated via RNAIII, binding of the response regulator protein AgrA to the psm loci directly enhances their transcription 28 . The peptide PSM-mec, which is produced by many MRSA and MRSE (methicillinresistant S. epidermidis) strains, represents an exception to the rule that PSM peptides are encoded in the core genome. This PSM is encoded adjacent to the mecA-mecR-mecI gene cluster in staphylococcal cassette chromosome mec (SCCmec; an MGE conferring methicillin resistance) types II, III and VIII 29, 30 (FIG. 1ac . Interestingly, similar to the RNAIII-encoded δ-toxin, the coding sequence for PSM-mec is embedded within a regulatory RNA 31 , one function of which is to inhibit translation of AgrA 32 , resulting in decreased expression of other PSMs. However, this activity is highly strain dependent 30, 32 .
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PSM export
All PSMs are secreted without a signal peptide, carrying an amino-terminal N-formyl methionine. The formyl group can be removed by cytosolic N-deformylase in a reaction that is dependent on culture conditions 33 and seems to happen to a more pronounced extent in S. aureus than in S. epidermidis 16 . The lack of a signal peptide indicates that PSM secretion takes place by a dedicated mechanism, which was recently identified to be a four-component ABC transporter 34 (FIG. 3) . This transporter plays an essential part in S. aureus physiology because in its absence, PSM peptides accumulate in the cytosol, leading to cell death. Most phenolsoluble modulins (PSMs) are regulated tightly by the accessory gene regulator (Agr) system, a quorum sensing system that produces and senses the presence of a post-translationally modified pheromone called autoinducing peptide (AIP). The necessary components of the Agr system are encoded by the agrBDCA operon. The response regulator AgrA activates transcription of the agrBDCA operon in an autofeedback loop, and also of rNAIII, the effector molecule in charge of changing the transcription levels of most genes in the Agr operon. The psmα and psmβ genes are the only known and confirmed exceptions, as they are directly regulated by AgrA, indicating an early evolutionary link between quorum sensing and PSM production, and suggesting that rNAIII-dependent gene regulation was added later in evolution by formation of the rNAIIIencoding genetic information around the δ-toxin gene (hld). The psmmec gene in the staphylococcal cassette chromosome mec (SCCmec) element is also under Agr control, but it is not known whether this occurs by direct binding of AgrA. The transporter, named Pmt (PSM transporter), secretes all PSMs in S. aureus, and the presence of Pmt homologues in other staphylococcal species indicates a conserved role for Pmt in PSM secretion among the staphylococci. Interestingly, there are no Pmt homologues in other genera. This might explain why PSM production is limited to the genus Staphylococcus: owing to the essentiality of the transporter in the presence of PSM production, the evolution of PSM peptides seems to have been possible only in the presence of, or with the co-evolution of, an efficient secretion system.
PSMs and pathogenicity
The PSMα peptides of S. aureus have a key impact on the capacity of virulent S. aureus to cause skin infection and bacteraemia in animal infection models 7, 8 . This was demonstrated using the CA-MRSA strains S. aureus USA300 and S. aureus USA400, which have enhanced virulence compared with hospitalassociated MRSA (HA-MRSA) strains; these two CA-MRSA strains have emerged during the past decade and can infect otherwise healthy individuals 35 . δ-toxin had a moderate effect and PSMβ peptides no effect in these studies 7 . Furthermore, all S. aureus PSM peptides and the S. epidermidis PSMβ peptides facilitate the dissemination of biofilm-associated infections to other organs in the human body 22, 23 . Other S. epidermidis psm loci have not yet been assayed for their contribution to virulence using deletion mutants. Together, these findings indicate that PSM peptides have a strong impact on the pathogenesis of major staphylococcal disease types and have undergone divergent evolution to develop specific functions in pathogenesis.
PSM-mediated cytolysis. The ability to lyse eukaryotic cells is arguably the most important contribution of PSMs to S. aureus pathogenesis (FIG. 4) . It is likely to be a receptor-independent process 11 , thus targeting almost every eukaryotic cytoplasmic membrane and distinguishing PSMs from other cytolytic S. aureus toxins, such as α-toxin or the two-component leukocidins, which are both often highly specific for a particular cell type and host species 36 . Not all S. aureus PSMs are cytolytic, however. The PSMα peptides of S. aureus have a pronounced ability to lyse human leukocytes and erythrocytes, and PSMα3 has by far the strongest activity 7, 37 , δ-toxin has moderate cytolytic activity, and the PSMβ peptides are non-cytolytic. These differences seem to correlate at least in part with the charge characteristics of PSMs (FIG. 1) , but which structural features of PSMs define their biological activities has not yet been analysed in detail. Notably, for the highly virulent CA-MRSA strains S. aureus USA300 and S. aureus USA400, deletion of the psmα operon decreases the cytolytic capacity towards human neutrophils to levels found in S. aureus 252, a standard HA-MRSA strain; moreover, expression of PSMα peptides or PSMα3 alone at physiological levels in S. aureus 252 leads to a cytolytic capacity similar to that found in CA-MRSA strains 7 . Furthermore, CA-MRSA strains show, on average, higher in vitro expression of PSMs, especially of the cytolytic PSMα peptides 38 . Together with the results from the animal models described above, these findings indicate that PSMs contribute considerably to the high virulence potential of CA-MRSA and probably also to that of other virulent S. aureus strains.
S. epidermidis is much less cytolytic than S. aureus 16 . Accordingly, the level of cytolytic PSMs produced by S. epidermidis is very low. Instead, non-cytolytic PSMβ peptides are expressed at much higher levels in S. epidermidis than in S. aureus 16 . In that regard, it is interesting that S. epidermidis encodes a strongly cytolytic PSM peptide, PSMδ, but PSMδ expression levels are low 16 . The expression patterns of PSMs were analysed in more than 30 S. aureus strains covering many different lineages and in more than 300 strains of S. epidermidis, and PSM expression always showed a similar pattern 29 . The PSM production pattern thus seems to reflect the lifestyle of a staphylococcal species, and pronounced production of the strongly cytolytic PSMs, as measured in culture filtrates, is limited to S. aureus. This also suggests that the different approaches of S. epidermidis and S. aureus to causing human disease might be the result of not only an overall paucity of toxins in S. epidermidis compared with in S. aureus 4 , but also adaptation of biological activities within the PSM toxin family.
Although the PSMα peptides of S. aureus have a demonstrated key role in pathogenesis 7, 8, 39 , the role of cytolysis in that situation is unclear. Binding to lipoproteins in human serum has been shown to diminish the cytolytic capacity of PSMs 40 . These peptides might still exhibit cytolytic ability in other extracellular environments, such as in a skin abscess, but the fact that such activity is diminished in serum suggests that cytolytic PSMs exert their contribution to pathogenesis to a large extent in the intracellular environment. In fact, several studies have demonstrated that PSMα peptides of S. aureus facilitate neutrophil killing after phagocytosis 34, 41, 42 (FIG. 4) and, very recently, within osteoblasts 39 . Owing to the phenomenon of 'diffusion sensing' , the Agr system has been predicted to be strongly expressed in the neutrophil phagosome 43 , leading to strong expression of the Agr-regulated PSMs. However, the stringent response seems to be the primary signal triggering upregulation of PSMs in that context 42 , rather than Agr. Traditional vaccines work by enhancing antibody-mediated uptake of bacteria by phagocytes. However, this is not correlated with bacterial survival after phagocytosis, which is what ultimately determines the outcome of an infection. Thus, the pronounced capacity to kill phagocytes after uptake -a hallmark of virulent S. aureus strains such as CA-MRSA strains 35 and now mechanistically linked to PSMs 34,41,42 -might provide some explanation for why attempts to develop traditional S. aureus vaccines have failed 44 .
PSMs and biofilm development. Bacterial biofilms have a characteristic spongy structure with channels that are important for the delivery of nutrients to deeper layers and, thus, for the survival of cells in biofilms. Cell density-dependent gene regulation (that is, quorum sensing), mediated by the Agr system in staphylococci, has long been implicated as a regulatory mechanism governing the formation of the channel-containing biofilm structure [45] [46] [47] [48] [49] . However, the underlying molecular factors have remained elusive. Recent research indicates that bacterial biofilms are structured by the activity of Phenol-soluble modulins (PSMs) are secreted by the four-component ABC transporter Pmt (PSM transporter). Presence of the Pmt transporter is crucial for PSM-mediated phenotypes, such as cytolysis, inflammation and biofilm structuring, and for immunity to self and non-self PSMs. In analogy to other transporters that export membrane-active drugs , the substrate is likely to be bound from within the membrane, using the same mechanism for PSMs originating from the cytosol and those from the surrounding fluid. (FIG. 4) . In S. aureus, all PSMs have biofilm-structuring activities, indicating that -as expectedthey influence biofilm development via their shared physico-chemical properties 22 . PSM expression can also result in biofilm dispersal (that is, the detachment of cells or cellular clusters from biofilms), which is a key mechanism leading to the systemic dissemination of infections involving biofilms 7, 22 . Interestingly, some S. aureus PSMs have been reported to form fibril-like structures under specific in vitro culture conditions, leading to enhanced biofilm accumulation 50 . At first glance, this observation seems to contradict the impact of PSMs on biofilm structuring and dispersal, but it is possible that the role of PSMs in biofilm development in vitro and in vivo is multifaceted, combining several different modes of action.
Antimicrobial activities. Some PSMs, such as S. epidermidis PSMδ and δ-toxin, have antimicrobial activity, including activity against Streptococcus pyogenes 51 (FIG. 4) . However, the fact that high concentrations of PSMs are needed to detect such activity indicates that PSMs have not evolved to become antimicrobials. Proteolytic processing strongly increases the antimicrobial activities of S. aureus PSMα1 and PSMα2, which have little antimicrobial activity in their unprocessed forms 52 . Whether these antimicrobial derivatives of PSMα1 and PSMα2 occur in vivo is not known. In general, S. pyogenes seems to be the species that is most sensitive to the antimicrobial activity of PSMs, but the molecular reasons for this sensitivity are not understood. PSMs thus potentially contribute to bacterial interference in vivo, and in particular interference with streptococci. Notably, staphylococci are protected from the anti microbial activities of PSM by the Pmt secretion system, which confers immunity to the self-produced PSM and also to PSMs produced by potential co-colonizers 34 .
PSMs and immunomodulation. PSMs are cytolytic for neutrophils in the micromolar range. At nanomolar concentrations, they stimulate leukocytes and initiate proinflammatory responses, including neutrophil chemoattraction and activation, and the release of interleukin-8 (IL-8) 7, 11 . Therefore, PSMs can be regarded as pathogen-associated molecular patterns (PAMPs). It is likely that the neutrophil-attracting properties of PSMs are important in local S. aureus infections and contribute to inflammation (FIG. 4) .
Leukocytes sense PSMs via N-formyl-peptide receptor 2 (FPR2) 11 , which had not previously been implicated in antibacterial host defence 53 . Unlike the paralogous FPR1, which responds to all bacteria by binding bacteriumspecific formylated peptides, FPR2 has a low affinity for formylated peptides and responds instead to certain human peptides involved in chronic inflammation 53 . Of note, PSMs were found to be among the most potent of all known FPR2 agonists 11 . As this activity is shared by all PSMs despite their low sequence similarity, FPR2 might sense the amphiphatic, α-helical structure of PSMs rather than a specific amino acid sequence motif. Among other bacterial genera, FPR2 responds only to certain enterococcal strains 54 and to Listeria monocytogenes 55 , although activation seems to be much lower than that exerted by staphylo cocci 54 . However, PSM-related genes and the PSM exporter gene locus, pmt, are found only in staphylococcal genomes, indicating that these enterococcal strains and L. monocytogenes (which are Gram-positive pathogens) secrete other types of peptide ligands for FPR2.
The response of FPR2 to culture filtrates of different staphylocococcal species correlates well with the virulence potential and level of PSM release by the various strains: the Figure 4 | overview of phenol-soluble modulin activities. In a probably receptor-independent manner and in the micromolar range, phenol-soluble modulins (PSMs) cause biofilm structuring and detachment, spreading on surfaces, and cytolysis. Some PSMs are also antibacterial, in particular towards streptococci. Cytolytic activity is found exclusively in α-type PSMs. owing to the receptor-independent nature of this cytolytic activity, it is likely that many cell types are subject to destruction by PSMs. erythrocytes and neutrophils are shown as examples. Lysis of neutrophils by α-type PSMs can occur after phagocytosis, making PSMs a particularly valuable weapon against elimination by innate host defence. PSMs also affect the adaptive immune system by inducing a tolerogenic phenotype in dendritic cells (DCs) and inhibiting T helper 1 (T H 1) cell differentiation. In the nano molar range, all PSMs activate N-formyl-peptide receptor 2 (FPR2), leading to neutrophil activation, chemotaxis and cytokine release.
response is strong towards highly pathogenic CA-MRSA, moderate towards HA-MRSA and opportunistic pathogens such as S. epidermidis and Staphylococcus saprophyticus, and hardly detectable towards commensals such as Staphylococcus auricularis 17 . Therefore, it was proposed that FPR2 not only detects PAMPs but also monitors the pathogenicity of the invading bacterium to appropriately adjust the immune response. In line with this notion, inhibition of the probable mouse FPR2 orthologue, FPRRS2, abrogates neutrophil influx in local infections caused by PSMproducing S. aureus USA300 or in response to locally injected PSM peptides 11 . Dendritic cells (DCs), which connect innate and adaptive immunity, also express FPR2 and are attracted by PSMs. Intriguingly, PSMs induce a tolerogenic phenotype in DCs, characterized by reduced antigen endocytosis, increased IL-10 secretion and inhibition of pro-inflammatory cytokine release 56 . As a consequence, PSM-treated DCs inhibit T helper 1 (T H 1) cell differentiation and induce regulatory T cells, thereby probably contributing to the immune evasion capacities of highly virulent S. aureus (FIG. 4) . However, the latter activities seem to be FPR2 independent, suggesting that either interactions with other receptors or PSM-dependent perturbations of host cell membranes mediate the anti-inflammatory activity of PSMs in DCs.
The various and partly contrasting ways in which PSMs affect leukocyte functions raise the question of how these activities interact and whether the pathogen or the host profits from a particular interaction. When only small numbers of bacteria initiate a local infection, the low amounts of secreted PSMs are likely to be in the range that is sensed by FPR2, eliciting neutrophil influx and chemokine production. This process probably contributes to the clearance of infections caused by staphylococcal strains with low virulence potential. By contrast, highly virulent strains with strong PSM expression subsequently destroy phagocytes and modulate the activity of immigrating DCs, thereby subverting innate and adaptive immune responses.
S. aureus produces two proteins, FLIPr and FLIPr-like, that block FPR2 activation 57, 58 , emphasizing the importance of FPR2 for the host during S. aureus infection. However, the human lipid mediator lipoxin can also block FPR2 (REF. 59 ), suggesting that the host needs to control FPR2 activation. Furthermore, reactive oxygen species produced by activated neutrophils might abrogate the immunomodulatory effects of PSMs 60 . The exact biological role of host interference with the immunomodulatory activities of PSMs remains to be elucidated.
Targeting PSMs for drug development
The strong impact that PSMs, and especially PSMα peptides, have on the development of acute forms of S. aureus disease identifies these peptides as promising targets for drug development. Several routes using PSMs as drug targets can be envisaged.
First, PSMs could be used as antigens in active vaccination approaches. These peptides offer the advantages that they are secreted and crucial to virulence. Similar efforts are being undertaken using other important secreted toxins of S. aureus, such as α-toxin 61 . However, these approaches are based on the assumption that efficient protective memory against S. aureus can be developed, which remains a challenge for the generation of vaccines.
As a second route, PSMs could be targeted by monoclonal antibodies (mAbs). For the reasons outlined above, mAb-dependent facilitation of opsonophagocytosis might not lead to enhanced killing of S. aureus. However, mAbs might eliminate PSM toxicity by sequestration. For an anti-PSM mAb formula to have high efficacy, the mAbs would need to work against the most cytolytic PSMs, but it is unlikely that mAbs can be developed that react with all PSMα peptides, owing to the lack of epitope similarity. However, it would potentially be enough to target the main cytolysin, PSMα3. Furthermore, this method will certainly not be able to efficiently attack PSMs that are produced inside the neutrophil phagosome, because it is unlikely that sufficient amounts of sequestering anti-PSM mAbs would be ingested together with the bacteria to counteract PSM toxicity after phagocytosis. Moreover, at least in the blood, mAbs might not add much to the effect of lipoproteins in sequestering PSMs. Thus, the success of a mAb approach is dependent on a strong contribution of PSMs to disease in the extracellular environment. Because the relative contributions of different mechanisms of PSM action to disease development are poorly understood, these considerations indicate the necessity of further research in that area.
As a third route to using PSMs as drug targets, the discovery of the Pmt secretion system could facilitate the development of strategies to interfere more efficiently and broadly with PSM production. Targeting Pmt would have the benefits of abolishing the production of all PSMs simultaneously, in addition to directly causing cell death.
Drugs blocking the Pmt transport function might even work on all PSM-producing species, as the Pmt system is well conserved. Both small molecules and mAbs should be evaluated as Pmt blockers. As there are far fewer copies of Pmt than there are PSMs, it is possible that Pmt can be sufficiently blocked inside the neutrophil phagosome by mAbs that are co-ingested. In addition, Pmt could be a target for active vaccination, given its surface location and essential role in growth and pathogenesis. Other S. aureus transport systems with or without a demonstrated function in pathogenesis are being or have been evaluated as candidate vaccines 62, 63 . However, further development of the transporter-targeted Aurograb vaccine (Novartis) was stopped at the clinical trial stage, as has been the case for all other S. aureus vaccine candidates so far 64 . Finally, the recognition of PSMs by FPR2 might be a target for therapeutic intervention, as FPR2 blockers might reduce inflammation. However, assessing the value of such intervention requires further research delineating whether the PSM-FPR2 interaction is part of the staphylococcal pathogenesis programme or whether it benefits the host.
Concluding remarks
PSMs have been recognized as key players in staphylococcal pathogenesis, influencing a series of virulence mechanisms (FIG. 4) involved in a range of disease manifestations. There are several unanswered questions about the role of PSMs in pathogenesis and during noninfectious colonization, and future research on PSMs should address these areas. First, we do not yet understand exactly the nature of the putative original role of PSMs in the commensal lifestyle of staphylococci. Research in that direction will have to use better animal models of colonization that are more representative of the situation in vivo. However, such models are difficult to develop. Second, a more detailed analysis of the mechanisms by which PSMs contribute to specific diseases will be required, including addressing whether and when they work in the extracellular and intracellular environments and which additional cell types are affected by PSM activities. Third, it remains enigmatic why staphylococci always produce arrays of α-type and β-type PSM peptides with largely identical activities. Moreover, the seemingly contrasting roles of PSMs during interactions with innate host defences need specific attention. Finally, PSMs should be developed as targets for antistaphylococcal drugs, and work in this area will benefit from a deeper understanding of the functions of PSMs in pathogenesis.
